Clinical Trial Update: PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage [Phase 2]

View source ↗

Summary

Phase 2 trial comparing PEG-ASP+Gemoxd versus PEG-ASP+CHOP as first-line chemotherapy for early-stage NK/T-cell lymphoma; status and results not provided in sum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Natural Killer T-cell Lymphoma

Drugs mentioned

• PEG-ASP+CHOP
• PEG-ASP+Gemoxd

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN